ArticleLeukemia research2015

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Talha Badar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.